| Autor: |
Giuseppe Armentaro, Graziella D’Arrigo, Marcello Magurno, Alfredo F. Toscani, Valentino Condoleo, Sofia Miceli, Velia Cassano, Raffaele Maio, Franco Arturi, Giovanni Tripepi, Giorgio Sesti, Angela Sciacqua |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Frontiers in Pharmacology, Vol 12 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
1663-9812 |
| DOI: |
10.3389/fphar.2021.733475 |
| Popis: |
Heart failure (HF) represents a widespread health problem characterized by high morbidity and mortality. Sacubitril/Valsartan (sac/val) has improved clinical prognosis in patients affected by HF with reduced ejection fraction (HFrEF). The aim of this study was to evaluate the effectiveness and durability of sac/val treatment on the clinical, hemodynamic and echocardiographic parameters, in real-life consecutive HFrEF outpatients, evaluated up to 2-years of follow-up. We collected 300 repeated observations over time in 60 patients suffering of HFrEF and symptomatic despite optimal drug therapy. Patients with left ventricular ejection fraction (LVEF) |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
